We all know that THC increases our appetite. But what about CBD? As it turns out , CBD has a surprising effect on metabolism. THC is associated with stimulating hunger causing munchies, this cannabinoid is capable of influencing metabolism. But does CBD affect. The urinary excretion profile of CBD metabolism has been reported only for a single case, which involved a dystonic patient chronically treated.
metabolism cbd for
While first-pass metabolism could be avoided by rectal administration of suppository formulation of CBs, as it has been demonstrated for THC, 46 , 47 relevant studies with CBD appear to be lacking. In these cases, however, factors influencing CB pharmacokinetics were unknown. No information is available for tissue distribution of CBD or its metabolites in living humans and relevant animal studies are scarce. In rats, analysis of blood and brain A recent study compared plasma and brain levels of CBD after oral or intraperitoneal i.
Oral administration offered six times higher brain peak CBD concentrations in rats than in mice 8. The effects of cosolvents and excipients on pharmacokinetics, involving cytochrome P CYP oxidases and P-glycoprotein efflux transporters, of lipophilic substances in general have been extensively investigated.
It must be noted that none of the above studies reported on the metabolic fate of CBD and no information is available on the human pharmacokinetics of the metabolites.
For an early mouse study indicating slow elimination of unidentified polar metabolites, see Karler et al. Subsequently, the use of sophisticated analytical techniques, especially GC-MS and, occasionally, reliance on synthetic standards for structure confirmation allowed the unequivocal identification of CB metabolites in humans see below. Being a good substrate of CYP mixed function oxidases, CBD undergoes extensive hydroxylation at multiple sites and further oxidations result in a complex metabolic pattern; altogether, some CBD metabolites have been identified from various organisms.
Following initial excretion studies, 32 , 58 about 40 oxygenated human Phase I metabolites have been characterized. The O -glucuronide conjugate of CBD was one of the most abundant urinary excretion products A further nonoxidized CB, probably a cyclized monophenol, was also detected at 1.
Figure 2c lists five side-chain monohydroxylated CBD metabolites, which were recently identified in a human liver preparation in vitro 60 ; all of them had been known from previous animal studies. The enzymatic processes responsible for the formation of the metabolites involve CYP oxidases, glucuronyl transferases and sulfotransferases, of which the CYP enzyme family has only been thoroughly studied. Sulfation of CBD species may also occur but such conjugates remain unknown.
Studies should thus use appropriate hydrolysis before Phase I metabolite quantification. Finally, it should be mentioned that interindividual differences in the expression and function of CYP enzymes may considerably affect the pharmacokinetics of CBD and its metabolites, and this could be relevant in the therapeutic action and any possible adverse effects of CBD-containing preparations.
One of the interesting metabolites of CBD is cannabielsoin Fig. The atypical quinone HU was found to inhibit mouse hepatic microsomal CYP enzymes, 78 CYP3A11 in particular, 79 as well as induced apoptosis of splenocytes isolated from mice.
HU also has antiangiogenic properties and is a selective inhibitor of topoisomerase II. There have been only a few in vivo investigations with selected monooxygenated metabolites. HU, which has been postulated to be a short-lived re active oxidative metabolite of CBD with CYP inhibitory properties, 79 , 80 has been extensively investigated in rodents due to its anticancer activity.
There are no publications describing the biological activity of CBD metabolites in humans. The pharmacological actions of CBD on receptors, ion channels, cellular uptake processes, and enzymes have recently been reviewed 9—11 and are not reiterated here.
Since CBD is often administered concomitantly with other medicines, for example, as an adjunct in the therapy of certain diseases, drug—drug interactions should be taken into account.
What follows is a brief summary of such effects possibly having relevance in the clinical use of CBD. The contentious issue of CBD—THC interaction, however, is not discussed here for a brief summary, see the relevant section in a recent review The first pharmacological effect to be observed for CBD was, in fact, related to drug interaction.
It has repeatedly been demonstrated that CBD is not only a substrate but also an inhibitor of CYP enzymes, and thus, it could interfere with the metabolism of other xenobiotics, including THC and medicinal products. The presence and role of CBD metabolites in the observed drug interactions have not been reported. Recently, an 8-week trial studied the interaction of the anticonvulsant drug clobazam and CBD in 13 children with refractory epilepsy.
Furthermore, CBD has been shown to interact in vitro with P-glycoprotein efflux transporters involved in multidrug resistance, and thus, it may affect the pharmacokinetics of anticancer drugs. The identification of CBD metabolites has typically relied on mass spectral fragmentation patterns, and structural confirmation by synthesis was done only in a few cases; nevertheless, essentially all single-site modified CBD metabolites have been prepared.
The aim of most of these syntheses was merely to verify the chemical structure of a metabolite and not to provide material for bioassays. The few exceptional studies were discussed in the preceding paragraphs. Analytical characterizations of and synthetic methodologies for all five metabolites hydroxylated at the pentyl side chain were described in the early s. Chemical syntheses of metabolites oxidized at multiple sites have not been published.
Several drugs used in therapy are metabolically converted into active metabolites and interindividual variations in the generation and pharmacokinetics of such active species may cause variability in the response to treatment by different individuals. Pharmacological studies with such metabolites are scarce yet suggest interesting biological activities, which are unrelated or not directly related to CB receptors. Thus, intriguing questions arise:.
Could any of the pharmacological effects observed for CBD be attributed to its metabolites? Are there any drug—drug interactions that affect the outcome of the therapeutic effects of other, non-CB medicines used concomitantly with CBD? Could any of the metabolites be used as templates for the development of novel therapeutic agents? The pharmacological characterization of CBD metabolites both in vitro and in vivo is timely and necessary to shed light on the multifaceted, perplexing, or sometimes even contradictory biological properties observed for the parent CB.
The understanding of the clinical significance of these abundant metabolites in the proven therapeutic effects of CBD-containing preparations warrants further studies. Michael Evans-Brown is gratefully acknowledged for linguistic advice. Cite this article as: National Center for Biotechnology Information , U. Journal List Cannabis Cannabinoid Res v. Published online Mar 1. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC.
Associated Data Supplementary Materials Supplemental data. Abstract Cannabidiol CBD , the main nonpsychoactive constituent of Cannabis sativa , has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy.
Open in a separate window. Human Pharmacokinetics of CBD Upon Various Administration Routes Extensive studies in animals, including rodents and the dog, indicate that a large portion of the administered CBD is excreted intact or as its glucuronide. Chemical structures of CBD-derived substances of biological interest. Studies in animals There have been only a few in vivo investigations with selected monooxygenated metabolites. Human studies There are no publications describing the biological activity of CBD metabolites in humans.
Interaction with other drugs The pharmacological actions of CBD on receptors, ion channels, cellular uptake processes, and enzymes have recently been reviewed 9—11 and are not reiterated here.
Synthesis of CBD Metabolites The identification of CBD metabolites has typically relied on mass spectral fragmentation patterns, and structural confirmation by synthesis was done only in a few cases; nevertheless, essentially all single-site modified CBD metabolites have been prepared.
Summary Several drugs used in therapy are metabolically converted into active metabolites and interindividual variations in the generation and pharmacokinetics of such active species may cause variability in the response to treatment by different individuals. Thus, intriguing questions arise: Supplementary Material Supplemental data: Click here to view. Acknowledgment Michael Evans-Brown is gratefully acknowledged for linguistic advice. Author Disclosure Statement No competing financial interest.
Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. Jacob A, Todd AR. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. Mechoulam R, Shvo Y. The structure of cannabidiol. ElSohly M, Gul W. Constituents of Cannabis sativa. Handbook of Cannabis Pertwee RG, editor. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish.
Known pharmacological actions of nine nonpsychotropic phytocannabinoids. Molecular targets of cannabidiol in neurological disorders. Cannabidiol CBD and its analogs: Safety and side effects of cannabidiol, a Cannabis sativa constituent. Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Cannabidiol for neurodegenerative disorders: Br J Clin Pharmacol. Cannabidiol as potential anticancer drug. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.
Gloss D, Vickrey B. Cochrane Database Syst Rev. The biology and potential therapeutic effects of cannabidiol. Food and Drug Administration.
Warning letters and test results. Community register of orphan medicinal products: Metabolism and pharmacokinetics of the cannabinoids. Biochemistry and physiology of substance abuse Watson RR, editor. Boca Raton, , pp. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids.
Cannabinoid pharmacokinetics and disposition in alternative matrices. A review of the literature. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intraveous administration. Biomed Environ Mass Spectrom. Metabolism of cannabinoids in man. New York, , pp. Assay of cannabinol and cannabidiol by mass fragmentography.
Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
Controlled clinical trial of cannabidiol in Huntington's disease. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. Research suggests that CBD may exert some of its pharmacological action through its inhibition of fatty acid amide hydrolase FAAH , which may in turn increase the levels of endocannabinoids , such as anandamide , produced by the body.
The drug was approved by Health Canada in for prescription to treat central neuropathic pain in multiple sclerosis , and in for cancer related pain. Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid. CBD was isolated from the cannabis plant in , and its chemical structure was established in Cannabidiol is the generic name of the drug and its INN.
Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop.
Some growers in the U. Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids.
The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0. Cannabidiol is not scheduled under the Convention on Psychotropic Substances or any other UN drug treaty.
In addition, in the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs , which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis , other than the separated resin whether crude or purified obtained from the plant. In September , following its approval by the FDA for rare types of childhood epilepsy,  Epidiolex was rescheduled by the Drug Enforcement Administration as a Schedule V drug to allow for its prescription use.
The Farm Bill  legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program. Prescription medicine Schedule 4 for therapeutic use containing 2 per cent 2. A schedule 4 drug under the SUSMP is Prescription Only Medicine, or Prescription Animal Remedy — Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.
It is also a prescription medicine under the Medicines Act. In the rules were changed so that anyone wanting to use it could go to the Health Ministry for approval.
Prior to this, the only way to obtain a prescription was to seek the personal approval of the Minister of Health.
Associate Health Minister Peter Dunne said restrictions would be removed, which means a doctor will now be able to prescribe cannabidiol to patients. On October 17, , cannabidiol became legal for recreational and medical use. Several industrial hemp varieties can be legally cultivated in Western Europe. CBD is classified as a medical product in Sweden. Cannabidiol, in an oral-mucosal spray formulation combined with deltatetrahydrocannabinol, is a product available by prescription only until for relief of severe spasticity due to multiple sclerosis where other anti- spasmodics have not been effective.
Until , products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body , the Medicines and Healthcare products Regulatory Agency MHRA and could not be marketed without regulatory approval for the medical claims.
A literature review indicated that cannabidiol was under basic research to identify its possible neurological effects,  although as of [update] , there was limited high-quality evidence for such effects in people. From Wikipedia, the free encyclopedia.
Not to be confused with Cannabinol or Cannabinodiol. S4 Prescription only UK: Schedule I except Epidiolex, Schedule V. Drug culture Illegal drug trade Psychedelia. Retrieved 28 June Journal of Clinical Pharmacology. Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders".
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences Review. State of the art and new challenges for therapeutic applications". Implications for Treating Anxiety-Related Disorders". Journal of Natural Products. US Food and Drug Administration. Retrieved 25 June Retrieved 1 November Hard Evidence at Last?
Annals of Clinical Psychiatry. A Systematic Review of the Evidence". British Journal of Clinical Pharmacology. A Comprehensive Update of Evidence and Recommendations".
American Journal of Public Health. Cannabis and Cannabinoid Research. Drug Metabolism and Disposition. Journal of Biological Chemistry. British Journal of Pharmacology. Naunyn-Schmiedeberg's Archives of Pharmacology. Therapeutics and Clinical Risk Management. On the nature of the Beam test".
Structure elucidation of four pyrolytic products , doi: An improved synthesis of cannabidiol". Journal of Experimental Botany. Food and Drug Administration.
Retrieved January 2, Trends in Pharmacological Sciences. Department of Agriculture, State of Colorado. Retrieved 14 September Cannabidiol is illegal and always has been".
Retrieved December 10, Retrieved 14 May National Conference of State Legislatures. Retrieved 13 January Retrieved 6 November Retrieved January 3, The Farm Bill. Retrieved January 29, Retrieved December 4, Retrieved June 2,
CBD And Metabolism
However, it turns out that the non-psychoactive part of the hemp plant (CBD) may affect our metabolism in a quite different way! If you're not. This article is sponsored by CV Sciences, Inc. CV Sciences is one of the leading suppliers and manufacturers of agricultural hemp-derived CBD. Protein binding: Not Available; Metabolism. THC and CBD are metabolized in the liver by a number of cytochrome P isoenzymes, including CYP2C9.